Sandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics
- Sandoz to acquire three established brands sold in more than 100 markets
- Acquisition, including leading global brand Zinnat®, confirms Sandoz commitment to antibiotics, following plans to expand its integrated manufacturing site in Kundl
- Transaction complements Sandoz leadership in generic penicillins with a leading position in cephalosporins – largest antibiotic segment by global sales
Basel, February 11, 2021 – Sandoz, a Novartis division, has signed an agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics.
The agreement includes the global rights to three established brands (Zinnat®, Zinacef® and Fortum®)) in more than 100 markets. It excludes the rights in the US, Australia and Germany to certain of those brands, which were previously divested by GSK, and in India, Pakistan, Egypt, Japan (to certain of the brands) and China, which will be retained by GSK.
Sandoz will pay GSK USD 350 million at closing, plus additional milestone payments of up to USD 150 million, subject to the terms of the transaction. Closing of the transaction is expected in the second half of 2021, subject to customary closing conditions including regulatory approvals. In 2020, the three brands had combined sales of approximately USD 140 million in the relevant markets.
In line with its integrated manufacturing strategy, Sandoz intends in the longer term to manufacture Zinnat® at sites in its own network, which has global antibiotics production centered on its lead production site in Kundl, Austria. Once the transaction is completed, GSK will supply Zinnat® to Sandoz under a manufacturing and supply agreement (MSA), while supporting a transfer of the related manufacturing operations to Sandoz. We expect this process to last for approximately four years from the close of the transaction onwards.
“This important transaction will further position Sandoz as a global leader in antibiotics – truly essential medicines that are the backbone of modern healthcare systems,” said Sandoz CEO Richard Saynor.
“Cephalosporins are the largest antibiotic segment by global sales and acquiring this leading business, including the established global Zinnat® brand, will complement our #1 position in generic penicillins, the other key segment. It will also set us up for additional synergies driven by an increased promotional footprint that will support growth of both the acquired brands and the current existing Sandoz portfolio.”
The agreement confirms the Sandoz commitment to further grow its antibiotics business, following the announcement last year of a joint investment with the Austrian government of more than EUR 150 million to strengthen the long-term competitiveness of its Kundl antibiotic manufacturing site and help to ensure long-term supply resilience.
Kundl is the hub and center of the last major integrated production chain for antibiotics in the western world. Its focus is on generic penicillin products, but the plant also produces finished dosage forms of several generic cephalosporin products.
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plans,” “commitment,” “to acquire,” “to expand,” “expected,” “intends,” “expect,” “focus,” or similar terms, or by express or implied discussions regarding the agreement to acquire GSK’s cephalosporin antibiotics business; or regarding potential future revenues from Zinnat, Zinacef or Fortum. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the transaction described in this press release will be completed in the expected time frame, or at all. Neither is there any guarantee that the expected benefits or synergies from such transaction will be achived in the expected timeframe, or at all. Nor can there be any guarantee that Zinnat, Zinacef or Fortum will be commercially successful in the future. In particular, our expectations regarding the transaction described in this press release and Zinnat, Zinacef and Fortum could be affected by, among other things, the satisfaction of customary closing conditions including regulatory approvals; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering major therapeutic areas, accounted for 2020 sales of USD 9.6 billion.
Sandoz on social media:
CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor/
Sandoz Global Communications
Sandoz Global Communications
+49 174 244 9501 (mobile)
Sandoz Global Communications
+1 973 714 8043
Novartis Media Relations
Novartis Communications and Engagement
+44 7966 118 652
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
|Samir Shah||+41 61 324 7944||Sloan Simpson||+1 862 778 5052|
|Thomas Hungerbuehler||+41 61 324 8425|
|Isabella Zinck||+41 61 324 7188|
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
RESULT OF RIKSBANK CERTIFICATE SALE9.3.2021 10:15:00 CET | Press release
AuctionAuction resultsAuction date2021-03-09Start date2021-03-10Maturity date2021-03-17Interest rate, %0.00 %Offered volume, SEK bn380.0Total bid amount, SEK bn1888.6Accepted volume, SEK bn380.0Number of bids16Percentage alloted, %20.121 %
Results Extraordinary General Meeting9.3.2021 08:30:00 CET | Press release
PRESS RELEASE: Amsterdam – 9 March 2021.Intertrust N.V. (“Intertrust”) [Euronext: INTER], a global leader in providing tech-enabled corporate and fund solutions to clients operating and investing in international business, announces that in the Extraordinary General Meeting (EGM) of 8 March 2021 the shareholders adopted all voting items on the agenda. Chief Executive Officer Shankar Iyer was appointed as member of the Management Board of Intertrust. Mr. Iyer’s appointment has been approved by Dutch regulators and is effective immediately, for a first term of four years. At the EGM a total of 74.32% of the total issued share capital was represented. The results of the votes for each item on the agenda, will be published on our website https://www.intertrustgroup.com/investors/shareholder-information/extraordinary-general-meeting-march-2021/. Draft minutes of the EGM will be published no later than three months after the end of the meeting, after which shareholders should have the opport
Van Lanschot Kempen: update on share buy-back programme 2 March 2021 – 8 March 20219.3.2021 08:30:00 CET | Press release
Amsterdam/’s-Hertogenbosch, the Netherlands, 9 March 2021 In the period from 2 March 2021 until 8 March 2021 Van Lanschot Kempen has repurchased 16,381 of its own shares (depositary receipts for Class A ordinary shares). The shares were repurchased at an average price of €21.80 per share for a total amount of €358,433. These repurchases are part of the share buy-back programme for at most 400,000 of own shares, which was announced on 25 February 2021. The total number of shares repurchased to date is 41,381. More information, including a detailed overview of the repurchase transactions under this programme, is available on www.vanlanschotkempen.com/sharebuyback. Media Relations: +31 20 354 45 85; email@example.com Investor Relations: +31 20 354 45 90; firstname.lastname@example.org About Van Lanschot Kempen Van Lanschot Kempen, a wealth manager operating under the Van Lanschot, Kempen and Evi brand names, is active in Private Banking, Asset Management and Me
GrandVision publishes Annual Report 2020 and convocation for virtual AGM9.3.2021 08:00:00 CET | Press release
GrandVision publishes Annual Report 2020 and convocation for virtual AGM Schiphol, the Netherlands - 9 March 2021. GrandVision N.V. (EURONEXT: GVNV) today announced that it has published its Annual Report 2020 including the Financial Statements 2020. The Annual Report is available for download and in digital form on GrandVision’s website: annualreport2020.grandvision.com. GrandVision has also published the convocation for the Annual General Meeting of Shareholders (AGM) on its website (www.grandvision.com). The AGM will be held on 23 April 2020. Due to the continued impact of the COVID-19 pandemic, the meeting will be held virtually, and shareholders will not be able to attend the AGM in person at a physical location. By using this format, GrandVision is following recommendations to forgo major events and to protect the health of shareholders, employees and all other stakeholders. Details of how shareholders can exercise their shareholder rights under these special circumstances are se
Kalmar receives repeat order of AutoStrads from Patrick Terminals9.3.2021 08:00:00 CET | Press release
CARGOTEC CORPORATION, PRESS RELEASE, 9 MARCH 2021 AT 9 AM (EET) Kalmar, part of Cargotec, is to supply a total of twelve new Kalmar AutoStrad™ units to Patrick Terminals. The order for the fully automated straddle carriers was booked in Cargotec's 2021 Q1 order intake, with delivery of the machines scheduled to be completed during Q2 of 2022. Patrick Terminals is Australia's leading container terminal operator, handling over three million TEUs annually. The company operates some of Australia's most technologically advanced terminals at four strategically located ports: Brisbane AutoStrad Terminal, Sydney AutoStrad Terminal, Melbourne Terminal and Fremantle Terminal in Western Australia. In November 2019 Patrick Terminals signed a comprehensive software maintenance and support agreement with Kalmar covering the equipment automation systems at Brisbane and Sydney. Of the twelve new 8th generation Kalmar AutoStrads, five will operate at Brisbane and seven at Sydney. The machines are part
Ahold Delhaize share buyback update9.3.2021 08:00:00 CET | Press release
Zaandam, the Netherlands, March 9, 2021 – Ahold Delhaize has repurchased 1,693,300 of Ahold Delhaize common shares in the period from March 1, 2021 up to and including March 5, 2021. The shares were repurchased at an average price of €21.93 per share for a total consideration of € 37.1 million. These repurchases were made as part of the €1 billion share buyback program announced on November 4, 2020. The total number of shares repurchased under this program to date is 11,368,600 common shares for a total consideration of € 262.9 million. Download the share buyback transactions excel sheet for detailed individual transaction information from www.aholddelhaize.com/en/investors/share-information/share-buy-back-programs/ This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(2) of the EU Regulation that contains technical standards for buyback programs.
Pandora Trading Update for February 20219.3.2021 08:00:00 CET | Press release
Pandora today releases a trading update for February 2021. The trading update is, as the January trading update, released as a press release, and not a company announcement, per instructions from NASDAQ Copenhagen. Pandora has previously communicated that the company would, when relevant, release extraordinary trading updates due to the elevated uncertainty related to COVID-19. During February, the number of stores closed due to COVID-19 decreased from around 30% at the beginning of the month to around 25% by the end of the month. In February, the organic growth was 12% and total sell-out growth was 7% compared to February 2020. This translates into a quarter to date organic growth of 4% and total sell-out growth of 1%. Compared to February 2019, organic growth was 10% and total sell-out growth was -2% (quarter to date 5% and -6% respectively). Pandora is pleased with the performance so far in 2021. Considering that 25-30% of the stores were closed during January and February, the unde